Department of Endocrine Oncology and Nuclear Medicine, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Radiology Department II, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Endokrynol Pol. 2024;75(2):170-178. doi: 10.5603/ep.98488. Epub 2024 Apr 22.
The latest World Health Organization (WHO) classification from 2022 distinguishes the division of low-risk thyroid neoplasms such as non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP), follicular tumour of uncertain malignant potential (FT-UMP), and well-differentiated tumour of uncertain malignant potential (WDT-UMP). The final diagnosis is made postoperatively according to histopathologic results. The aim of the study was the assessment of ultrasonographic and cytopathological features of borderline lesions to predict low-risk tumours preoperatively and plan the optimal treatment for that group of patients.
A total of 35 patients (30 women; 5 men), aged 20-81 years with a mean age of 49 years, were enrolled in the study. The study evaluated 35 focal lesions of the thyroid gland, classified as low-risk neoplasms according to the WHO 2022 classification: FT-UMP (n = 21), NIFTP (n = 7), and WDT-UMP (n = 7). Ultrasonographic features of nodules including contrast-enhanced ultrasound (CEUS) and elastography were assessed by 2 specialists, and the risk of malignancy was evaluated according to EU-TIRADS-PL classification.
Of the 35 focal thyroid lesions, most were categorised as low or intermediate risk of malignancy according to EU-TIRADS-PL, with dominant category 3 [n = 13 (37.2%)] and category 4 [n = 15 (42.8%)]. High-risk category 5 was assessed in 7 lesions (20%). In cytopathology nodules were categorised as follows (Bethesda System TBSRTC 2023): Bethesda II (n = 4), Bethesda III (n = 2), Bethesda IV (n = 25), Bethesda V (n = 3), and Bethesda VI (n = 1). In the CEUS study, contrasting patterns dominated compared to the surrounding parenchyma, such as enhancement equal to the parenchyma (66.6%) or intense (28.5%), heterogeneous (61.9%), centripetal (42.8%), or diffuse (57.1%) with fast (33.3%) or compared to parenchyma contrast wash-in (42.8%) and its fast (33.3%) or comparable to thyroid parenchyma wash-out (52.3%).
The study indicates that lesions with uncertain malignant potential typically present features suggesting low to intermediate risk of malignancy based on EU-TIRADS-PL classification, with dominant cytopathologic Bethesda IV category. However, 20% of lesions were assessed tas EU-TIRADS-PL category 5. Low-risk tumours, including NIFTP, FT-UMP, and WDT-UMP, require careful observation and monitoring post surgical treatment due to their potential for recurrence and metastasis. The preoperatively prediction of borderline tumour may play an important role in proper treatment and follow-up.
2022 年世界卫生组织(WHO)的最新分类将低风险甲状腺肿瘤(如非浸润性滤泡性甲状腺肿瘤伴乳头状核特征(NIFTP)、滤泡性肿瘤具有不确定的恶性潜能(FT-UMP)和分化良好的肿瘤具有不确定的恶性潜能(WDT-UMP)区分开来。最终诊断是根据组织病理学结果在术后做出的。本研究的目的是评估边界病变的超声和细胞病理学特征,以预测术前低风险肿瘤,并为该组患者制定最佳治疗方案。
共纳入 35 名(30 名女性;5 名男性)年龄 20-81 岁、平均年龄 49 岁的患者。该研究评估了 35 个甲状腺局灶性病变,根据 2022 年 WHO 分类为低风险肿瘤:FT-UMP(n = 21)、NIFTP(n = 7)和 WDT-UMP(n = 7)。两名专家评估了结节的超声特征,包括对比增强超声(CEUS)和弹性成像,根据 EU-TIRADS-PL 分类评估恶性肿瘤风险。
在 35 个甲状腺局灶性病变中,根据 EU-TIRADS-PL,大多数病变被归类为低或中恶性风险,主要类别为 3(n = 13,37.2%)和 4(n = 15,42.8%)。高危类别 5 评估了 7 个病变(20%)。细胞病理学中,结节分类如下(Bethesda 系统 TBSRTC 2023):Bethesda II(n = 4)、Bethesda III(n = 2)、Bethesda IV(n = 25)、Bethesda V(n = 3)和 Bethesda VI(n = 1)。在 CEUS 研究中,与周围实质相比,增强模式占主导地位,如与实质增强相等(66.6%)或强烈(28.5%)、不均匀(61.9%)、向心(42.8%)或弥漫(57.1%)、快速(33.3%)或与实质对比冲洗入(42.8%)及其快速(33.3%)或与甲状腺实质冲洗出(52.3%)相似。
该研究表明,具有不确定恶性潜能的病变通常根据 EU-TIRADS-PL 分类显示出低至中恶性风险的特征,主要是细胞学 Bethesda IV 类别。然而,20%的病变被评估为 EU-TIRADS-PL 类别 5。低风险肿瘤,包括 NIFTP、FT-UMP 和 WDT-UMP,由于其复发和转移的潜力,需要在手术后仔细观察和监测。术前对边界性肿瘤的预测可能在适当的治疗和随访中发挥重要作用。